Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Institutional and Insider Confidence Drives First Citizens BancShares Momentum

Robert Sasse by Robert Sasse
August 23, 2025
in Stocks
0
First Citizens BancShares Stock
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

First Citizens BancShares shares demonstrated notable strength in the previous trading session, closing at $1,901.42 after a robust gain of 2.60%. The significant trading activity, with a volume reaching $310 million, points toward substantial institutional involvement in the move.

Surging Institutional Investment

The ownership structure of First Citizens BancShares is heavily weighted toward major financial entities, with hedge funds and institutional investors collectively holding 78.01% of the outstanding shares. Recent quarterly filings reveal a consistent pattern of these large-scale investors expanding their stakes.

Recent activity from major institutions includes:
* Level Four Advisory Services LLC grew its position by 4.7% in Q1.
* Guggenheim Capital LLC boosted its holdings by 37.5% during the fourth quarter.
* Canada Life Assurance Co increased its stake by a notable 11.3%.

This concentrated buying activity from influential market players sends a powerful message about their growing confidence in the financial institution.

Insider Purchases Reinforce the Bullish Stance

Aligning with the institutional sentiment, company insiders have also been active in the market. Chief Executive Officer Frank B. Holding Jr. acquired 600 shares at a price of $1,698.75 per share. In an even more substantial move, major shareholder Olivia Britton Holding expanded her investment by 30.18%.

Such unified purchasing from those with intimate knowledge of the company’s operations is widely interpreted as a strong vote of confidence in its current valuation and future prospects.

Should investors sell immediately? Or is it worth buying First Citizens BancShares?

Rising Analyst Optimism

Market analysts are concurrently raising their expectations for the stock’s performance. Citigroup recently revised its price target upward to $2,050. JPMorgan Chase & Co. has set an even more optimistic target, projecting a fair value of $2,250 per share.

The consensus price target among analysts now stands at $2,338, suggesting an upside potential of nearly 25% over the coming twelve months. The stock maintains a consistent “Buy” rating across the board.

Technical Breakout and Shareholder Returns

The stock achieved a significant technical milestone yesterday by breaking through its 200-day moving average, situated at $1,988.09. It went on to reach a daily peak of $1,996.00. This decisive technical breach could be the catalyst for a new wave of positive momentum.

Trading within a 52-week range of $1,473.62 to $2,412.93, the equity exhibits considerable volatility, which also indicates significant opportunity for movement.

Furthermore, shareholders are set to benefit from a quarterly dividend distribution. A payment of $1.95 per share is scheduled for September 15. At the current share price, this dividend yields 0.4%.

Ad

First Citizens BancShares Stock: Buy or Sell?! New First Citizens BancShares Analysis from March 25 delivers the answer:

The latest First Citizens BancShares figures speak for themselves: Urgent action needed for First Citizens BancShares investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

First Citizens BancShares: Buy or sell? Read more here...

Tags: First Citizens BancShares
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Eli Lilly Stock
Stocks

Eli Lilly’s Strategic Diversification Amid Weight-Loss Drug Competition

November 18, 2025
Micron Stock
Stocks

Micron Shares Approach Peak: What Comes After the AI Rally?

November 18, 2025
Varonis Stock
Stocks

Varonis Shares Plunge Amidst Mixed Signals

November 18, 2025
Next Post
Duke Energy Stock

Duke Energy Shifts Strategy from Offshore Wind to Operational Efficiency

Ubiquiti Stock

Ubiquiti Shares Surge to Record High on Stellar Earnings Performance

Gentherm Stock

Institutional Investors Make Major Moves on Gentherm Stock

Recommended

Lockheed Martin Stock

Defense Giant Lockheed Martin Secures Billions in New Military Contracts

6 months ago
OKE stock news

Amalgamated Bank Increases Stake in CF Industries as Market Opinions Vary

3 years ago
IBM Stock

IBM’s AI Windfall Fails to Impress Stock Market

7 months ago
Blackstonecured Lending Fund Stock

Blackstone BDC Insider Purchase Defies Analyst Downgrades

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Figma Embraces Third-Party AI to Power Its Design Ecosystem

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

Evolent Health Bets on AI Leadership Amid Share Price Decline

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Trending

Gossamer Bio Stock
Analysis

Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026

by Kennethcix
March 25, 2026
0

The future of Gossamer Bio hinges on a critical regulatory discussion scheduled for June 2026. The biopharmaceutical...

SOXX ETF Stock

Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns

March 25, 2026
Fair Isaac Stock

Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

March 25, 2026
Figma Stock

Figma Embraces Third-Party AI to Power Its Design Ecosystem

March 25, 2026
BioNano Genomics Stock

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026
  • Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns
  • Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com